Lupin receives USFDA approval for inflammatory relief ointment
Lupin announced that it has received the approval from the United States Food and Drug Administration (USFDA) to market its Betamethasone Dipropionate Ointment USP (Augmented), 0.05 per cent.
Betamethasone Dipropionate Ointment USP (Augmented), 0.05% is a generic equivalent of Diprolene Ointment, 0.05 per cent, by Merck Sharp and Dohme Corp. The product is planned to be manufactured at the company’s Pithampur (Unit 3) facility. Betamethasone Dipropionate Ointment USP (Augmented), 0.05 per cent, is a corticosteroid, primarily indicated for the relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients equal to and above 13 years. The product has had an annual sales of around US$22 million in the U.S according to IQVIA MAT September 2019 findings.
Lupin is an innovation led transnational pharmaceutical company, developing and delivering a wide range of branded and generic formulations, biosimilar products, and APIs, globally. It is considered to be a significant player in the cardiovascular, diabetology, asthma, pediatric, CNS, Gl, Anti-Infective, and NSAID areas and holds a global leadership position in the Anti-TB segment as well.
On Friday, the stock of the company closed flat at Rs 770.30, down by 0.05 per cent or Rs 0.40 per share. The 52-week high is Rs 887.70 and 52-week low is Rs 646.20 on the BSE.